长江生命科技(00775.HK)新冠病毒检测试剂盒引入香港市场
长江生命科技(00775.HK)公布,已与新加坡科技研究院(A*Star)签订许可协议,在香港以至全球分销以CoV-2冠状病毒逆转录聚合(酉每)链式反应「RT-PCR」进行COVID-19测试的检测试剂盒。
产品预先配备RT-PCR反应所需之全部材料,包括引物探针混合物、(酉每)混合物、阳性对照,阴性对照及内部对照模板,从而简化检测过程及节省时间。每个检测试剂盒均备有进行200次反应的试剂份量,而且是全订制样式。
该检测试剂盒由A*Star及陈笃生医院共同研发,并已取得新加坡卫生科学局之临时认可於当地使用。自2020年2月以来,该试剂盒已获新加坡当地六家公立医院及一家私立医疗集团采用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.